Skip to main content
. 2018 Feb 22;5:37–43. doi: 10.1016/j.phro.2018.02.002

Fig. 5.

Fig. 5

The comparison between MItotal and EM is shown for (a) head-and-neck and (b) prostate clinical plans. In (c) and (d) the corresponding mean gantry speed and mean dose rate variations are shown.